Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dapansutrile · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose Selection | EXPERIMENTAL | Dapansutrile starting at 500 mg PO BID plus Pembrolizumab 200 mg IV every three weeks. Dose escalation is planned to a maximum of 1000 mg BID of dapansutrile + pembrolizumab. |
| Dose Expansion | EXPERIMENTAL | Dapansutrile at the RP2D plus Pembrolizumab 200 mg IV every three weeks |
| Name | Type | Description |
|---|---|---|
| Dapansutrile | DRUG | 500 mg tablet |
| Pembrolizumab | DRUG | Single-use vial containing 100 mg/4 mL of pembrolizumab |
Inclusion Criteria: 1. Has histologically or cytologically confirmed melanoma. 2. Has unresectable Stage III or Stage IV melanoma, per AJCC 8th Edition Staging Criteria, not amenable to local therapy. 3. Male or female participants who are at least 18 years of age on the day of signing informed con...
Top 20 of 51 competitors
Dapansutrile is an investigational small molecule being studied for the treatment of PD-1 refractory advanced melanoma. It is currently in Phase 1 clinical development as a combination therapy with pembrolizumab for patients whose melanoma has not responded to PD-1 inhibitor therapy.
Dapansutrile is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug in patients with advanced melanoma.
Dapansutrile is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and effectiveness in patients with PD-1 refractory advanced melanoma.
Dapansutrile is being evaluated in a Phase 1 clinical trial with the identifier NCT04971499. This study is investigating dapansutrile in combination with pembrolizumab in patients with PD-1 refractory advanced melanoma. The trial is active but not recruiting participants and is being conducted in the United States.
Dapansutrile is the primary name used for this investigational drug in clinical trials. No alternative names have been reported for this compound in the available clinical trial information.